Niemann-pick C1-like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis

Lin Jia, Yinyan Ma, Shunxing Rong, Jenna L. Betters, Ping Xie, Soonkyu Chung, Nanping Wang, Weiqing Tang, Liqing Yu

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Niemann-Pick C1-Like 1 (NPC1L1) mediates intestinal absorption of dietary and biliary cholesterol. Ezetimibe, by inhibiting NPC1L1 function, is widely used to treat hypercholesterolemia in humans. Interestingly, ezetimibe treatment appears to attenuate hepatic steatosis in rodents and humans without a defined mechanism. Over-consumption of a high-fat diet (HFD) represents a major cause of metabolic disorders including fatty liver. To determine whether and how NPC1L1 deficiency prevents HFD-induced hepatic steatosis, in this study, we fed NPC1L1 knockout (L1-KO) mice and their wild-type (WT) controls an HFD, and found that 24 weeks of HFD feeding causes no fatty liver in L1-KO mice. Hepatic fatty acid synthesis and levels of mRNAs for lipogenic genes are substantially reduced but hepatic lipoprotein-triglyceride production, fatty acid oxidation, and triglyceride hydrolysis remain unaltered in L1-KO versus WT mice. Strikingly, L1-KO mice are completely protected against HFD-induced hyperinsulinemia under both fed and fasted states and during glucose challenge. Despite similar glucose tolerance, L1-KO relative WT mice are more insulin sensitive and in the overnight-fasted state display significantly lower plasma glucose concentrations. In conclusion, NPC1L1 deficiency in mice prevents HFD-induced fatty liver by reducing hepatic lipogenesis, at least in part, through attenuating HFD-induced insulin resistance, a state known to drive hepatic lipogenesis through elevated circulating insulin levels.

Original languageEnglish (US)
Pages (from-to)3135-3144
Number of pages10
JournalJournal of Lipid Research
Volume51
Issue number11
DOIs
StatePublished - Nov 1 2010

Fingerprint

Lipogenesis
High Fat Diet
Fatty Liver
Nutrition
Liver
Fats
Insulin
Glucose
Fatty Acids
Dietary Cholesterol
Intestinal Absorption
Hyperinsulinism
Hypercholesterolemia
Insulin Resistance
Hydrolysis
Rodentia
Triglycerides
Genes
Cholesterol
Plasmas

Keywords

  • Ezetimibe
  • Insulin resistance
  • Intestinal cholesterol absorption
  • Nonalcoholic fatty liver disease
  • Obesity

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Cell Biology

Cite this

Niemann-pick C1-like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. / Jia, Lin; Ma, Yinyan; Rong, Shunxing; Betters, Jenna L.; Xie, Ping; Chung, Soonkyu; Wang, Nanping; Tang, Weiqing; Yu, Liqing.

In: Journal of Lipid Research, Vol. 51, No. 11, 01.11.2010, p. 3135-3144.

Research output: Contribution to journalArticle

Jia, Lin ; Ma, Yinyan ; Rong, Shunxing ; Betters, Jenna L. ; Xie, Ping ; Chung, Soonkyu ; Wang, Nanping ; Tang, Weiqing ; Yu, Liqing. / Niemann-pick C1-like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. In: Journal of Lipid Research. 2010 ; Vol. 51, No. 11. pp. 3135-3144.
@article{efd1beb07ed145fcb614f0249d10adfb,
title = "Niemann-pick C1-like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis",
abstract = "Niemann-Pick C1-Like 1 (NPC1L1) mediates intestinal absorption of dietary and biliary cholesterol. Ezetimibe, by inhibiting NPC1L1 function, is widely used to treat hypercholesterolemia in humans. Interestingly, ezetimibe treatment appears to attenuate hepatic steatosis in rodents and humans without a defined mechanism. Over-consumption of a high-fat diet (HFD) represents a major cause of metabolic disorders including fatty liver. To determine whether and how NPC1L1 deficiency prevents HFD-induced hepatic steatosis, in this study, we fed NPC1L1 knockout (L1-KO) mice and their wild-type (WT) controls an HFD, and found that 24 weeks of HFD feeding causes no fatty liver in L1-KO mice. Hepatic fatty acid synthesis and levels of mRNAs for lipogenic genes are substantially reduced but hepatic lipoprotein-triglyceride production, fatty acid oxidation, and triglyceride hydrolysis remain unaltered in L1-KO versus WT mice. Strikingly, L1-KO mice are completely protected against HFD-induced hyperinsulinemia under both fed and fasted states and during glucose challenge. Despite similar glucose tolerance, L1-KO relative WT mice are more insulin sensitive and in the overnight-fasted state display significantly lower plasma glucose concentrations. In conclusion, NPC1L1 deficiency in mice prevents HFD-induced fatty liver by reducing hepatic lipogenesis, at least in part, through attenuating HFD-induced insulin resistance, a state known to drive hepatic lipogenesis through elevated circulating insulin levels.",
keywords = "Ezetimibe, Insulin resistance, Intestinal cholesterol absorption, Nonalcoholic fatty liver disease, Obesity",
author = "Lin Jia and Yinyan Ma and Shunxing Rong and Betters, {Jenna L.} and Ping Xie and Soonkyu Chung and Nanping Wang and Weiqing Tang and Liqing Yu",
year = "2010",
month = "11",
day = "1",
doi = "10.1194/jlr.M006353",
language = "English (US)",
volume = "51",
pages = "3135--3144",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "11",

}

TY - JOUR

T1 - Niemann-pick C1-like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis

AU - Jia, Lin

AU - Ma, Yinyan

AU - Rong, Shunxing

AU - Betters, Jenna L.

AU - Xie, Ping

AU - Chung, Soonkyu

AU - Wang, Nanping

AU - Tang, Weiqing

AU - Yu, Liqing

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Niemann-Pick C1-Like 1 (NPC1L1) mediates intestinal absorption of dietary and biliary cholesterol. Ezetimibe, by inhibiting NPC1L1 function, is widely used to treat hypercholesterolemia in humans. Interestingly, ezetimibe treatment appears to attenuate hepatic steatosis in rodents and humans without a defined mechanism. Over-consumption of a high-fat diet (HFD) represents a major cause of metabolic disorders including fatty liver. To determine whether and how NPC1L1 deficiency prevents HFD-induced hepatic steatosis, in this study, we fed NPC1L1 knockout (L1-KO) mice and their wild-type (WT) controls an HFD, and found that 24 weeks of HFD feeding causes no fatty liver in L1-KO mice. Hepatic fatty acid synthesis and levels of mRNAs for lipogenic genes are substantially reduced but hepatic lipoprotein-triglyceride production, fatty acid oxidation, and triglyceride hydrolysis remain unaltered in L1-KO versus WT mice. Strikingly, L1-KO mice are completely protected against HFD-induced hyperinsulinemia under both fed and fasted states and during glucose challenge. Despite similar glucose tolerance, L1-KO relative WT mice are more insulin sensitive and in the overnight-fasted state display significantly lower plasma glucose concentrations. In conclusion, NPC1L1 deficiency in mice prevents HFD-induced fatty liver by reducing hepatic lipogenesis, at least in part, through attenuating HFD-induced insulin resistance, a state known to drive hepatic lipogenesis through elevated circulating insulin levels.

AB - Niemann-Pick C1-Like 1 (NPC1L1) mediates intestinal absorption of dietary and biliary cholesterol. Ezetimibe, by inhibiting NPC1L1 function, is widely used to treat hypercholesterolemia in humans. Interestingly, ezetimibe treatment appears to attenuate hepatic steatosis in rodents and humans without a defined mechanism. Over-consumption of a high-fat diet (HFD) represents a major cause of metabolic disorders including fatty liver. To determine whether and how NPC1L1 deficiency prevents HFD-induced hepatic steatosis, in this study, we fed NPC1L1 knockout (L1-KO) mice and their wild-type (WT) controls an HFD, and found that 24 weeks of HFD feeding causes no fatty liver in L1-KO mice. Hepatic fatty acid synthesis and levels of mRNAs for lipogenic genes are substantially reduced but hepatic lipoprotein-triglyceride production, fatty acid oxidation, and triglyceride hydrolysis remain unaltered in L1-KO versus WT mice. Strikingly, L1-KO mice are completely protected against HFD-induced hyperinsulinemia under both fed and fasted states and during glucose challenge. Despite similar glucose tolerance, L1-KO relative WT mice are more insulin sensitive and in the overnight-fasted state display significantly lower plasma glucose concentrations. In conclusion, NPC1L1 deficiency in mice prevents HFD-induced fatty liver by reducing hepatic lipogenesis, at least in part, through attenuating HFD-induced insulin resistance, a state known to drive hepatic lipogenesis through elevated circulating insulin levels.

KW - Ezetimibe

KW - Insulin resistance

KW - Intestinal cholesterol absorption

KW - Nonalcoholic fatty liver disease

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=78149348442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149348442&partnerID=8YFLogxK

U2 - 10.1194/jlr.M006353

DO - 10.1194/jlr.M006353

M3 - Article

VL - 51

SP - 3135

EP - 3144

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 11

ER -